Prescott Group Capital Management L.L.C. Has $8.78 Million Stock Position in OR Royalties Inc. $OR

Prescott Group Capital Management L.L.C. lowered its holdings in shares of OR Royalties Inc. (NYSE:OR) by 13.9% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 248,000 shares of the basic materials company’s stock after selling 40,000 shares during the period. OR Royalties comprises about 0.8% of Prescott Group Capital Management L.L.C.’s holdings, making the stock its 23rd biggest position. Prescott Group Capital Management L.L.C.’s holdings in OR Royalties were worth $8,777,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of OR. Assetmark Inc. acquired a new position in shares of OR Royalties during the 4th quarter worth $36,000. Caitlin John LLC acquired a new position in shares of OR Royalties during the 3rd quarter worth $78,000. Allworth Financial LP raised its holdings in shares of OR Royalties by 20.0% during the 4th quarter. Allworth Financial LP now owns 2,305 shares of the basic materials company’s stock worth $82,000 after buying an additional 384 shares in the last quarter. Merit Financial Group LLC bought a new stake in OR Royalties during the 3rd quarter worth $215,000. Finally, Flow Traders U.S. LLC bought a new stake in OR Royalties during the 3rd quarter worth $217,000. Institutional investors and hedge funds own 68.52% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. TD Securities restated a “hold” rating on shares of OR Royalties in a research report on Monday, February 23rd. Zacks Research lowered OR Royalties from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Royal Bank Of Canada restated an “outperform” rating and set a $56.00 price objective on shares of OR Royalties in a research report on Friday, April 10th. Scotiabank boosted their price objective on OR Royalties from $41.00 to $51.00 and gave the stock a “sector perform” rating in a research report on Monday, January 26th. Finally, Wall Street Zen lowered OR Royalties from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 11th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.50.

OR Royalties Stock Up 1.4%

Shares of OR stock opened at $36.00 on Thursday. The firm has a market capitalization of $6.75 billion, a P/E ratio of 26.86 and a beta of 0.71. OR Royalties Inc. has a twelve month low of $24.42 and a twelve month high of $48.06. The stock’s fifty day simple moving average is $38.55 and its 200 day simple moving average is $38.41.

OR Royalties (NYSE:OR) last released its quarterly earnings results on Wednesday, May 6th. The basic materials company reported $0.40 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.06. OR Royalties had a return on equity of 15.10% and a net margin of 78.09%.The firm had revenue of $102.83 million for the quarter, compared to analyst estimates of $103.27 million. As a group, equities research analysts expect that OR Royalties Inc. will post 1.4 EPS for the current fiscal year.

OR Royalties Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Tuesday, June 30th will be given a $0.065 dividend. This is a boost from OR Royalties’s previous quarterly dividend of $0.06. The ex-dividend date is Tuesday, June 30th. This represents a $0.26 dividend on an annualized basis and a dividend yield of 0.7%. OR Royalties’s dividend payout ratio is presently 16.42%.

OR Royalties Company Profile

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.